Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Double-masked, Placebo-controlled Study Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Immunogenicity Of Single Escalating Doses Of Rn6g In Patients With Dry, Age-related Macular Degeneration (Amd)

NCT00877032 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00877032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00877032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Double-masked, Placebo-controlled Study Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Immunogenicity Of Single Escalating Doses Of Rn6g In Patients With Dry, Age-related Macular Degeneration (Amd)
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2009
Completion date
July 31, 2011
Enrollment
57 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

age-related maculopathies, age-related maculopathy, eye diseases, macular degeneration, retinal degeneration